nach oben

Medical Oncology

Erschienen in:

01.12.2011 | Original Paper

Relationship of survivin to clinical drug resistance in Burkitt’s lymphoma of the head and neck region

verfasst von: Manal M. Zyada

Erschienen in: Medical Oncology | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

This study was designed to determine the potential role of survivin in the pathogenesis of Burkitt´s lymphoma (BL) and analyzing the relationship of its expression with response to therapy. The expression of survivin was investigated in seven archival tumor tissues of BL using the streptavidin–biotin complex technique. Immunohistochemical analysis showed that survivin expression was positive in 6 of 7 BL cases (85.7%). BL group with high survivin expression had poor response to chemotherapy than the group with low survivin expression (P = 0.005). The results suggest that apoptosis inhibition by survivin is a significant prognostic parameter of poor response to chemotherapy in Burkitt’s lymphoma.

Liu D, Shimonov J, Primanneni S, Lai Y, Ahmed T, Seiter K. t (8;14;18): a 3- way chromosome translocation in two patients with Burkitt’s lymphoma/leukemia. Mol Cancer. 2007;6:35.PubMedCrossRef

Burkitt D. A sarcoma involving the jaws in African children. British J Surg. 1958;46(197):218–23.CrossRef

Iwata S, Wada K, Tobita S, Gotoh K, Ito Y, et al. Quantitative analysis of Epstein-Barr virus (EBV)-related gene expression in patients with chronic active EBV infection. J Gen Virol. 2010;91:42–50.PubMedCrossRef

Yustein JT, Dang CV. Biology and treatment of Burkitt’s lymphoma. Curr Opin Hematol. 2007;14(4):375–81.PubMedCrossRef

LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene. 1998;17(25):3247–59.PubMedCrossRef

Yang J, Liu Fx, Yan XC. Research advances on inhibitor of apoptosis, survivin. Ai Zheng. 2003;22(7):771–4.PubMed

Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3(8):917–21.PubMedCrossRef

Zaffaroni N, Pennati M, Daidone MG. Survivin as a target for new anticancer interventions. J Cell Mol Med. 2005;9(2):360–72.PubMedCrossRef

Rohan S, Gallagher L, Akhtar M. Survivin: role in diagnosis, prognosis, and treatment of bladder cancer. Adv Anat Pathol. 2006;13(3):122–6.PubMedCrossRef

10.

Lin CY, Hung HC, Kuo RC, Chiang CP, Kuo MY. Survivin expression predicts poorer prognosis in patients with areca quid chewing-related oral squamous cell carcinoma in Taiwan. Oral Oncol. 2005;41(6):645–54.PubMedCrossRef

11.

Lens SM, Vader G, Medema RH. The case for Survivin as mitotic regulator. Curr Opin Cell Biol. 2006;18(6):616–22.PubMedCrossRef

12.

Wolanin K, Piwocka K. Role of survivin in mitosis. Postepy Biochem. 2007;53(1):10–8.PubMed

13.

WHO classification of tumours of haematopoietic and lymphoid tissues. In Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO Classification of Tumours. Lyon: France IARC Press; 2008.

14.

Parker AS, Kosari F, Lohse CM, et al. High expression levels of survivin protein are an independent predictor of poor outcome among patients treated surgically for clear cell renal cell carcinoma. Cancer. 2006;107:37–45.PubMedCrossRef

15.

Pathology and genetics of tumours of haematopoietic and lymphoid tissues. In Jaffe E, Harris N, Stein H, Vardiman J, editors. World Health Organization classification of tumors. Lyon: France IARC Press; 2001.

16.

Okada E, Murai Y, Matsui K, Isizawa S, Cheng C, et al. Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. Cancer Lett. 2001;163:109–16.PubMedCrossRef

17.

Frost M, Jarboe EA, Orlicky D, Gianani R, Thompson LC, et al. Immunohistochemical localization of survivin in benign cervical mucosa, cervical dysplasia, and invasive squamous cell carcinoma. Am J Clin Pathol. 2002;117:738–44.PubMedCrossRef

18.

Uren AG, Wong L, Pakusch M, Fowler KJ, Burrows FJ, et al. Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol. 2000;10:1319–28.PubMedCrossRef

19.

Giodini A, Kallio MJ, Wall NR, Gorbsky GJ, Tognin S, et al. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res. 2002;62:2462–7.PubMed

20.

Adida C, Recher C, Raffoux E, Daniel MT, Taksin AL, et al. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol. 2000;111:196–203.PubMedCrossRef

21.

Rodriguez JA, Span SW, Ferreira CG, Kruyt FA, Giaccone G. CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein survivin. Exp Cell Res. 2002;275:44–53.PubMedCrossRef

22.

Margulis V, Lotan Y, Shariat SF. Survivin: a promising biomarker for detection and prognosis of bladder cancer. World J Urol. 2008;26(1):59–65.PubMedCrossRef

23.

Bosch F, Lopez-Guillermo A, Campo E, Ribera JM, Conde E, Piris MA, et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer. 1998;82:567–75.PubMedCrossRef

24.

Duffy MJ, O’Donovan N, Brennan DJ, Gallagher WM, Ryan BM. Survivin: a promising tumor biomarker. Cancer Lett. 2007;249(1):49–60.PubMedCrossRef

25.

Kato J, Kuwabara Y, Mitani M, et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer. 2001;95:92–5.PubMedCrossRef

26.

Lens SM, Vader G, Medema RH. The case for Survivin as mitotic regulator. Curr Opin Cell Biol. 2006;18(6):616–22.PubMedCrossRef

27.

Caldas H, Honsey LE, Altura RA. Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer. 2005;4(1):11.PubMedCrossRef

28.

Kian TC, Miriam T, Richard Q, et al. Clinical characteristics, prognostic factors and outcomes of Burkitt lymphoma in adult Asians. Leuk Lymphoma. 2008;49:824–7.PubMedCrossRef

29.

Vegran F, Boidot R, Oudin C, Riedinger JM, Lizard-Nacol S. Implication of alternative splice transcripts of caspase-3 and survivin in chemoresistance. Bull Cancer. 2005;92(3):219–26.PubMed

Titel: Relationship of survivin to clinical drug resistance in Burkitt’s lymphoma of the head and neck region
verfasst von: Manal M. Zyada
Publikationsdatum: 01.12.2011
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 4/2011
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-010-9581-5

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Relationship of survivin to clinical drug resistance in Burkitt’s lymphoma of the head and neck region

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2011

Prognostic significance of clinical parameters and Epstein-Barr virus infection in non-endemic undifferentiated carcinoma of nasopharyngeal type: a Serbian report

Qualitative and quantitative promoter hypermethylation patterns of the P16, TSHR, RASSF1A and RARβ2 genes in papillary thyroid carcinoma

Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy

Pro-apoptotic protein BIM in apoptosis of glucocorticoid-sensitive and -resistant acute lymphoblastic leukemia CEM cells

Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer

Metastatic factors for Krukenberg tumor: a clinical study on 102 cases

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie